Did You Know...
...that "patent leather" got its name because the process of applying the polished black finish to leather was once patented?
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7291333 | Blockade of protein C activation reduces microvascular surgical blood loss A method of inhibiting microvascular bleeding is provided. Antibody to protein C administered to a patient in a pharmaceutically acceptable carrier prevents anticoagulation by greater than 90% of activated protein C in human plasma. ... | 11/06/2007 |
| 7271143 | Peptides for regulation of urokinase (uPA) and tissue type (tPA) plasminogen activator and method of optimizing therapeutic efficacy Compositions of the polypeptide SEQ ID NO:1, SEQ ID NO:2, anti-LRP antibodies, LRP antagonists, and/or one or more fibrinolytic agents are formulated for enhancing the fibrinolytic activity, reducing the side effects due to vasoactivity caused by the fibrinolytic ag... | 09/18/2007 |
| 7268110 | Agents for preventing and treating thrombocytopenia Method of increasing blood platelet formation by administering a parathyroid hormone (PTH) or at least one PTH derivative as an active ingredient. ... | 09/11/2007 |
| 7247707 | Albumin-free factor VIII formulations A Factor VIII composition formulated without albumin, comprising the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent select... | 07/24/2007 |
| 7101557 | Combined tissue factor methods for coagulation and tumor treatment The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositi... | 09/05/2006 |
| 7087723 | Albumin-free factor VIII formulations A Factor VIII composition formulated without albumin, comprising the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent select... | 08/08/2006 |
| RE39150 | Composition for creating vascular occlusions A composition including 2-hexyl cyanoacrylate and goal is useful in treating arteriovenous malformations (AVMs) and other body lumens to be blocked. ... | 06/27/2006 |
| 7041635 | Factor VIII polypeptide The application discloses Factor VIII polypeptides comprising internal deletions of amino acids within the area of residues 741 to 1689, wherein the thrombin cleavage sites at about 741 and about 1689 are present, and a site at about 1648 is not present, as compared... | 05/09/2006 |
| 7033994 | Medicinal compositions for preventing and treating hemorrhagic diseases associating thrombopathy The present invention provides a pharmaceutical composition for treatment and prevention of bleeding disorders caused by platelet disorders, not caused by defect in blood coagulation factors or von Willebrand Factor but caused by reduction of circulating platelet co... | 04/25/2006 |
| 7015193 | Compositions and methods to control bleeding Disclosed are compositions for treating blood coagulation disorders and allows for manipulation of the blood coagulation cascade. More particularly the invention, relates to compositions for altering bleeding that include a mixture of at least one blood coagulation ... | 03/21/2006 |
| 7005508 | Nitroderivatives of polysaccharides The present invention provides a new class of compounds presenting a high compatibility with tissues and organic fluids. Such new compounds are polysaccharides essentially formed of units of uronic acid and/or hexosamine, containing nitro groups —ONO2 c... | 02/28/2006 |
| 6967239 | Method of filtering viruses from a factor VIII solution Method for preparing a factor VIII solution that is essentially free of viruses and essentially devoid of vWF (von Willebrand factor) and factor VIII-vWF complexes by (a) obtaining a starting factor VIII solution devoid of factor VIII-vWF complexes; and (b) filterin... | 11/22/2005 |
| 6956022 | Agents for preventing and treating thrombocytopenia Method of increasing blood platelet formation by administering a parathyroid hormone (PTH) or at least one PTH derivative as an active ingredient. ... | 10/18/2005 |
| 6953837 | Factor VIII/vWF complexes and compositions There is disclosed a method of recovering factor VIII/vWF-complex which is characterized in that factor VIII/vWF-complex from a protein solution is bound to a cation exchanger and is recovered by step-wise elution of factor VIII/vWF-complex, which particularly conta... | 10/11/2005 |
| 6930087 | Pharmaceutical composition comprising factor VIII and neutral liposomes A pharmaceutical composition for parenteral administration comprising a therapeutically effective amount of a protein or polypeptide and substantially neutral colloidal particles. The particles comprise approximately 1-20 mole percent of an amphipathic lipid derivat... | 08/16/2005 |
| 6903069 | Factor VII glycoforms The present invention provides preparations of Factor VIIa polypeptides or Factor VIIa-related polypeptides that exhibit predetermined glycoform patterns. The preparations of the invention exhibit improved functional properties and are useful for treating Factor VII... | 06/07/2005 |
| 6884616 | DNA-construct for the tissue-specific expression of a blood coagulation factor A DNA-construct has been disclosed which is suitable for a tissue-specific expression of a blood coagulation factor like Factor IX, which comprises a DNA coding for an amino acid sequence of a blood coagulation factor and a DNA coding for a promoter which is specifi... | 04/26/2005 |
| 6855734 | Glycine betaine and its use Pharmaceutical uses of glycine betaine, such as for the treatment of thromboses not induced by hyperhomocystenemia or homocystinuria, of blood disorders, such as blood coagulation, thrombi formation. ... | 02/15/2005 |
| 6833352 | Coagulation factor Viia composition The invention relates to a pharmaceutical composition comprising Factor VIIa for subcutan, intramuscular or interdermal administration. Factor VIIa administered subcutanously, intramuscularly or intradermally shows a sufficient transport into the bloodstream ... | 12/21/2004 |
| 6797260 | Bleeding control and healing aid compositions and methods of use A composition is disclosed which has been shown to stop or control bleeding and seal open small blood vessels while accelerating the healing process of abraded oral “gum” and other “skin” (epithelial) tissues. The composition is preferably in the form of a p... | 09/28/2004 |
| 6780614 | Modified factor VIII cDNA and its use for the production of factor VIII A modified Factor VIII cDNA is disclosed wherein the B-domain of the wild type factor cDNA has been deleted and a truncated Factor IX intron 1 has been inserted in two locations of the Factor VIII cDNA and as a promoter a cDNA is used which is suitable for the expre... | 08/24/2004 |
| 6770744 | Modified factor VIII Specific amino acid loci of human factor VIII interact with inhibitory antibodies of hemophilia patients after being treated with factor VIII. Modified factor VIII is disclosed in which the amino acid sequence is changed by a substitution at one or more of the speci... | 08/03/2004 |
| 6652840 | Bleeding control and healing aid compositions and methods of use A composition is disclosed which has been shown to stop or control bleeding and seal open small blood vessels while accelerating the healing process of abraded oral "gum" and other "skin" (epithelial) tissues. The composition is preferably in the form of ... | 11/25/2003 |
| 6593294 | Pharmaceutical composition comprising Factor VIII and neutral liposomes A pharmaceutical composition for parenteral administration comprising a therapeutically effective amount of a protein or polypeptide and substantially neutral colloidal particles. The particles comprise approximately 1-20 mole percent of an amphipathic li... | 07/15/2003 |
| 6559133 | Use of flavone 8-acetic acid in vascular and cardiovascular interventions and acute coronary syndromes A method for treatment of a vascular or cardiovascular condition or acute coronary syndromes comprises administering an effective amount of a flavone 8-carboxylic acid to a mammal suffering from a vascular or cardiovascular condition or acute coronary syn... | 05/06/2003 |
| 6521265 | Method for applying a blood clotting agent A method of arresting the flow of blood and other protein containing body fluids flowing from an open wound and for promoting wound healing. In the method, a substantially anhydrous compound of a salt ferrate is provided for a unique use which, when hydra... | 02/18/2003 |
| 6458563 | Modified factor VIII The invention relates to a modified B-domainless form of porcine factor VIII, to a DNA encoding the same, and to the use thereof for treatment of hemophilia.... | 10/01/2002 |
| 6403556 | Pharmaceutical preparation containing protein C and a thrombolytically active substance A pharmaceutical preparation contains protein C and a thrombolytically active substance that does not activate protein C. This preparation prevents reocclusion usually occurring in the course of thrombolysis therapy.... | 06/11/2002 |
| 6391343 | Fibrinogen-coated particles for therapeutic use The invention provides a particle comprising fibrinogen bound on the surface of an albumin matrix, wherein said particle is capable of coaggregation with platelet, and of aggregation in a solution containing soluble fibrinogen at a concentration of solubl... | 05/21/2002 |
| 6346513 | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them Novel polypeptides having Factor VIII activity are provided as well as compositions and methods for their preparation. The polypeptides comprise derivatives and fragments of Factor VIII and have sequences substantially similar to portions of naturally occ... | 02/12/2002 |
| 6264988 | Fibrinogen-coated microspheres The invention provides compositions comprising microspheres of fibrinogen-coated cross-linked albumin microspheres having a size range of primarily from about 100 to about 5000 nanometers diameter, wherein the composition is substantially free microsphere... | 07/24/2001 |
| 6228613 | Stable factor VIII/von Willebrand factor complex There are disclosed a stable factor VIII/vWF-complex, particularly comprising high-molecular vWF multimers, being free from low-molecular vWF molecules and from proteolytic vWF degradation products, as well as a method of producing this complex.... | 05/08/2001 |
| 6132730 | Combined tissue factor and factor VIIa methods and compositions for coagulation and tumor treatment The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods an... | 10/17/2000 |
| 6132729 | Combined tissue factor and chemotherapeutic methods and compositions for coagulation and tumor treatment The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods an... | 10/17/2000 |
| 6130203 | Hybrid proteins with modified activity Hybrid proteins which affect blood coagulation comprise a region from a donor anticoagulant or antithrombotic protein, and the resulting hybrid protein has a modified biological activity. Information concerning the hybrid proteins implicates DNA sequences... | 10/10/2000 |
| 6110483 | Adherent, flexible hydrogel and medicated coatings The adherent coating of the invention comprises a stabilizing polymer together with an active agent (a hydrophilic polymer and/or a bioactive agent) in a layer bonded to the surface of a medical device. This invention encompasses the coating liquids used ... | 08/29/2000 |
| 6048720 | Conjugates of a polypeptide and a biocompatible polymer Processes for improving the in vivo function of factor VIII by shielding exposed targets of the factor VIII comprise a) immobilizing the factor VIII by interaction with a group-specific adsorbent carrying ligands manufactured by organic-chemical synthesis... | 04/11/2000 |
| 6037366 | Composition for creating vascular occlusions A composition including 2-hexyl cyanoacrylate and gold is useful in treating arteriovenous malformations (AVMs) and other body lumens to be blocked.... | 03/14/2000 |
| 6013620 | Pharmaceutical composition for the treatment of blood coagulation diseases, methods for the production thereof and its use The invention relates to a pharmaceutical composition for the treatment of patients with blood coagulation diseases which are caused by coagulation factor deficiency and/or inhibitors of coagulation factors, whereby the composition as a FEIB-activity and ... | 01/11/2000 |
| 5919766 | Composition comprising coagulation factor VIII formulation, process for its preparation and use of a surfactant as stabilizer The present invention relates to a novel composition comprising coagulation Factor VIII and a non-ionic surfactant such as block co-polymers, e.g. polyoxamers or polyoxyethylene (20) fatty acid esters e.g. polysorbate 20 or polysorbate 80 as a stabilizer.... | 07/06/1999 |
